<html>

<head>
  <title>MMPH15AGRX3276_CPS_Veeva_Email_v5_pfs_os</title>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />

  <style>
  a{
    outline:none;
    color:#004b7E;
  }

  ul{
    padding: 0 0 0 15px;
  }

  ul li{
    padding: 10px 0 0 0;
    color:#18BEE7;
    font-size:15px;
    font-family: sans-serif;

    /* Use bottom margins to place space between the list items */
    margin-bottom: 10px;
  }

  ul li span{
    font-family:Helvetica, Arial, sans-serif; 
    font-weight:200; 
    font-size:14px; 
    line-height: 1em; 
    color:#000000; 
    letter-spacing: 0px;
  }

  b{
    font-weight: 600;
  }

  u{
    text-decoration: underline;
  }

  .top-line{
    line-height: 25px; 
  }

  .orange-style-small{
    font-family:Arial, Helvetica, sans-serif; 
    font-weight:bold; 
    font-size:16px; 
    line-height: 22px; 
    color:#FF7A0F; 
    letter-spacing: 0.75px
  }

  .orange-style-large{
    font-family:Arial, Helvetica, sans-serif; 
    font-weight:100;
    font-size:30px; 
    line-height: 22px; 
    color:#FF7A0F; 
    letter-spacing: 0.27px;
  }

  .blue-style-small{
    font-family:Arial, Helvetica, sans-serif; 
    font-weight:bold; 
    font-size:16px; 
    line-height: 21px; 
    color:#004990; 
    letter-spacing: 0.75px
  }

  .blue-style-large{
    font-family:Arial, Helvetica, sans-serif; 
    font-weight:bold; font-size:30px; 
    line-height: 22px; 
    color:#004990; 
    letter-spacing: 0.27px;
  }

</style>
</head>

<body leftmargin="0" topmargin="0" marginwidth="0" marginheight="0" bgcolor="#000000">

<!-- wrapper -->
<table width="621" border="0" cellpadding="0" cellspacing="0" style="margin: 0 auto;">
<tr>
<td>

<!-- line above from -->
<table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#B7B7B7">
  <tr>
    <td>
      <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="1">
    </td>
  </tr>
</table>

<!-- from top border -->
<table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#DDDDDD">
  <tr>
    <td>
      <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="30">
    </td> 
  </tr>
  <tr>
</table>

<!-- from: -->
<table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#DDDDDD">
  <tr>

    <td >
      <img style="display:block;" src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="35" height="100%">
    </td>

    <td width="85">
      <font style="font-family:Arial, Helvetica, sans-serif; font-weight:bold; font-size:12px; line-height: 19px; color:#000000; letter-spacing: 0.75px;"> 
          From:<br />
          Date:<br />
          To:<br />
          Subject:
      </font>
    </td>

    <td>
      <img style="display:block;" src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="10" height="1">
    </td>

    <td>
      <font style="font-family:Arial, Helvetica, sans-serif; font-weight:normal; font-size:12px; line-height: 19px; color:#000000; letter-spacing: 0.75px"> 
          [HOC Name] &#60;noreply&#64;celgeneinfo.com&#62;<br />
          [Month, date, year]<br />
          [Dr. John Doe]<br />
          PFS and OS in patients with newly diagnosed MM
      </font>
    </td>

  </tr>
</table>

<!-- from bottom border -->
<table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#DDDDDD">
  <tr>
    <td>
      <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="30">
    </td> 
  </tr>
  <tr>
</table>

<!-- line below from -->
<table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#B7B7B7">
  <tr>
    <td>
      <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="100%" height="1">
    </td>
  </tr>
</table>

<!-- Revlimid Logo -->
<table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FCC147">
  <tr>
    <td>
      <a href="http://www.revlimid.com/mm-hcp/" target="_blank">
        <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/MMPH15AGRX3276_OralDosing_Veeva_Email_v7_05.png" width="289" height="201" border="0">
      </a>
    </td>

    <td>
      <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/MMPH15AGRX3276_OralDosing_Veeva_Email_v7_42.png" width="332" height="201" border="0">
      </td>
    </tr>
  </tr>
</table>

<!-- start with top border -->
<table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#004B7E">
  <tr>
    <td>
      <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="10">
    </td> 
  </tr>
</table>

<!-- start with -->
<table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#004B7E">
  <tr>

    <td>
      <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="30" height="1">
    </td>

    <td>
      <font style="font-family:Arial, Helvetica, sans-serif; font-weight:600; font-size:19px; line-height: 26px; color:#FFFFFF; letter-spacing: 1.5px"> 
        Rd CONTINUOUS SIGNIFICANTLY REDUCED THE<br />
        RISK OF PROGRESSION OR DEATH<small><sup style="vertical-align: top; position: relative; top: -0.6em;">1</sup></small>
      </font>
    </td>   
  </tr>
</table>

<!-- start with bottom border -->
<table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#004B7E">
  <tr>
    <td>
      <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="10">
    </td> 
  </tr>
</table>

<!-- yellow spacer row -->
<table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FCC!47">
<tr>
    <td>
      <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="6">
    </td>
</tr>
</table>

<!-- double table -->
<table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FDC238">
<tr>

    <!-- left table content -->
    <td width="397" valign="top">

       <!-- 28% reduced risk top border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FCC!47">
      <tr>
          <td>
              <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="15">
          </td>
        </tr>
      </table>
      <!-- end 28% reduced risk top border -->

      <!-- 28% reduced risk -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FDC238">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="30" height="1">
          </td> 
          <td>
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:400; font-size:18px; line-height: 22px; color:#004B7E; letter-spacing: .2px">
              28% reduced risk of progression or death<br />
              with Rd Continuous
            </font>
          </td>
        </tr>
      </table>
      <!-- end 28% reduced risk -->

      <!-- 28% reduced risk bottom border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FCC147">
      <tr>
          <td>
              <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="10">
          </td>
        </tr>
      </table>
      <!-- end 28% reduced risk bottom border -->


      <!-- Chart headline top border-->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#004B7E">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="20">
          </td> 
        </tr>
      </table>
      <!-- end Chart headline top border-->

      <!-- Chart headline -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#004B7E">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="30" height="1">
          </td> 
          <td> 
              <font style="font-family:Arial, Helvetica, sans-serif; font-weight:600; font-size:15px; line-height: 18px; color:#FFFFFF; letter-spacing: 1px"> 
                Reduced Risk of Progression or Death
              </font>
          </td>
        </tr>
      </table>  
      <!-- end chart headline-->

      <!-- chart top border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#064C7C">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="20">
          </td> 
        </tr>
      </table>
      <!-- end chart top border -->

      <!-- chart -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#064C7C">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="30" height="1">
          </td> 
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/reduced-risk.png" width="365" height="389" alt="">
          </td>

        </tr>
      </table>
      <!-- end calendar -->

      <!-- chart bottom border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#064C7C">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="25">
          </td> 
        </tr>
      </table>
      <!-- end chart bottom border -->

      <!-- top bullet list top border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FDC238">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="10">
          </td> 
        </tr>
      </table>
      <!-- end top bullet list top border -->

      <!-- top bullet list -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FDC238">      
        <tr>
          <td width="39" height="10"  style="text-align:right; vertical-align:tocenter; padding: 0 5px 0 0;">
              <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/bullet.png" width="7" height="6">
          </td> 
          <td width="364" height="10" bgcolor="#FDC238">
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:normal; font-size:14px; line-height: 17px; color:#004B7E; letter-spacing: 0.40px">
              Median progression-free survival was 25.5 months for
          </td> 
        </tr>

        <tr>
          <td width="39" height="10" bgcolor="#FDC238" style="text-align:right; vertical-align:top;">
          </td> 
          <td width="364" height="10" bgcolor="#FDC238">
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:normal; font-size:14px; line-height: 17px; color:#004B7E; letter-spacing: 0.40px">
              Continuous Rd vs 21.2 months for MPT (HR 0.72 [95% 
          </td>
        </tr>

        <tr>
          <td width="39" height="10" bgcolor="#FDC238" style="text-align:right; vertical-align:top;">
          </td> 
          <td width="364" height="10" bgcolor="#FDC238">
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:normal; font-size:14px; line-height: 17px; color:#004B7E; letter-spacing: 0.40px">
                 CI 0.61, 0.85]; P&#60;0.0001) and 20.7 months for Rd18
          </td>    
        </tr>

        <tr>
          <td width="39" height="10" bgcolor="#FDC238" style="text-align:right; vertical-align:top;">
          </td> 
          <td width="364" height="10" bgcolor="#FDC238">
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:normal; font-size:14px; line-height: 17px; color:#004B7E; letter-spacing: 0.40px">
                 (HR 0.70 [95% CI 0.60, 0.82])
          </td>    
        </tr>

        <!-- spacer row -->
        <tr>
          <td width="1" height="10" bgcolor="#FDC238">
              <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="7" height="6">
          </td> 
        </tr>

        <!-- treatment should -->
        <tr>
          <td width="40" height="10" bgcolor="#FDC238" style="text-align:right; vertical-align:tocenter; padding: 0 5px 0 0;">
              <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/bullet.png" width="7" height="6">
          </td> 

          <td width="364" height="10" bgcolor="#FDC238">
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:normal; font-size:14px; line-height: 17px; color:#004B7E; letter-spacing: 0.40px">
              The primary efficacy comparison was between the 
            </font>
          </td>
        </tr>

        <tr>
          <td width="40" height="10" bgcolor="#FDC238" style="text-align:right; vertical-align:top;padding: 3px 5px 0 0;">
          </td> 

          <td width="364" height="10" bgcolor="#FDC238">
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:normal; font-size:14px; line-height: 17px; color:#004B7E; letter-spacing: 0.40px">
              Rd Continuous and MPT arms
            </font>
          </td>
        </tr>
      </table>
      <!-- end top bullet list -->

      <!-- top bullet list bottom border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FDC238">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="10">
          </td> 
        </tr>
      </table>
      <!-- end top bullet list bottom border -->

      <!-- PFS top border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FECB67">
      <tr>
          <td>
              <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="10">
          </td>
        </tr>
      </table>
      <!--end  PFS top border -->


      <!-- PFS -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FECB67">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="30" height="1">
          </td> 
          <td>
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:400; font-size:12px; line-height:15px; color:#004B7E; letter-spacing: .2px">
              PFS was defined as the time from randomization to the first documentation of disease as determined by Independent Response Adjudication Committee (IRAC), based on International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurred first during the study until the end of the PFS follow-up phase.
            </font>
          </td>
        </tr>
      </table>
      <!-- end PFS-->

      <!-- PFS bottom border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FECB67">
      <tr>
          <td>
              <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="10">
          </td>
        </tr>
      </table>
      <!-- end PFS bottom border -->

      <!-- Rd continuious #2 top border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#064C7C">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="25">
          </td> 
        </tr>
      </table>
      <!-- Rd continuious #2 top border -->

      <!-- Rd continuious -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#004B7E">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="25" height="1">
          </td> 
          <td> 
              <font style="font-family:Arial, Helvetica, sans-serif; font-weight:600; font-size:15px; line-height: 18px; color:#FFFFFF; letter-spacing: 1.5px"> 
                Rd Continuous reduced the risk of death<br />
                by 25% vs MPT<sup style="vertical-align: top; position: relative; top: -0.25em;">1</sup>
              </font>
          </td>
        </tr>
      </table>  
      <!-- end Rd continuious #2-->

      <!-- arrow image top border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#064C7C">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="25">
          </td> 
        </tr>
      </table>
      <!-- end arrow image top border -->

      <!-- arrow image -->
      <table width="100%" cellpadding="0" cellspacing="0" bgcolor="#064C7C">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="70" height="1">
          </td> 
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/down-arrow.png" width="151" height="151">
          </td>
        </tr>
      </table>
      <!-- end arrow image -->

      <!-- arrow image top bottom border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#064C7C">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="29">
          </td> 
        </tr>
      </table>
      <!-- end arrow image top bottom border -->

      <!-- bullet list #2 top border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FDC238">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="10">
          </td> 
        </tr>
      </table>
      <!-- end bullet list #2 top border -->

      <!-- bullet list #2 -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FDC238">      
        <tr>
          <td width="39" height="10"  style="text-align:right; vertical-align:tocenter; padding: 0 5px 0 0;">
              <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/bullet.png" width="7" height="6">
          </td> 
          <td width="364" height="10" bgcolor="#FDC238">
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:normal; font-size:14px; line-height: 17px; color:#004B7E; letter-spacing: 0.40px">
              Median overall survival was 58.9 months for
          </td> 
        </tr>
        <tr>
          <td width="39" height="10" bgcolor="#FDC238" style="text-align:right; vertical-align:top;">
          </td> 
          <td width="364" height="10" bgcolor="#FDC238">
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:normal; font-size:14px; line-height: 17px; color:#004B7E; letter-spacing: 0.40px">
              Continuous Rd vs 48.5 months for MPT (HR 0.75
          </td>
        </tr>

        <tr>
          <td width="39" height="10" bgcolor="#FDC238" style="text-align:right; vertical-align:top;">
          </td> 
          <td width="364" height="10" bgcolor="#FDC238">
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:normal; font-size:14px; line-height: 17px; color:#004B7E; letter-spacing: 0.40px">
              [95% CI 0.62, 0.90]) and 56.7 months for Rd18 
          </td>    
        </tr>

        <tr>
          <td width="39" height="10" bgcolor="#FDC238" style="text-align:right; vertical-align:top;">
          </td> 
          <td width="364" height="10" bgcolor="#FDC238">
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:normal; font-size:14px; line-height: 17px; color:#004B7E; letter-spacing: 0.40px">
              (HR 0.91 [95% CI 0.75, 1.09])
          </td>    
        </tr>
        <!-- spacer row -->
        <tr>
          <td width="1" height="10" bgcolor="#FDC238">
              <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="7" height="6">
          </td> 
        </tr>
        <tr>
          <td width="40" height="10" bgcolor="#FDC238" style="text-align:right; vertical-align:tocenter; padding: 0 5px 0 0;">
              <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/bullet.png" width="7" height="6">
          </td> 

          <td width="364" height="10" bgcolor="#FDC238">
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:normal; font-size:14px; line-height: 17px; color:#004B7E; letter-spacing: 0.40px">
              For patients who are ASCT-eligible, hematopoietic
            </font>
          </td>
        </tr>
        <tr>
          <td width="40" height="10" bgcolor="#FDC238" style="text-align:right; vertical-align:top;padding: 3px 5px 0 0;">
          </td> 

          <td width="364" height="10" bgcolor="#FDC238">
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:normal; font-size:14px; line-height: 17px; color:#004B7E; letter-spacing: 0.40px">
              stem cell mobilization should occur within 4 cycles
            </font>
          </td>
        </tr>
        <tr>
          <td width="40" height="10" bgcolor="#FDC238" style="text-align:right; vertical-align:top;padding: 3px 5px 0 0;">
          </td> 

          <td width="364" height="10" bgcolor="#FDC238">
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:normal; font-size:14px; line-height: 17px; color:#004B7E; letter-spacing: 0.40px">
              of a REVLIMID-containing therapy
            </font>
          </td>
        </tr>

      </table>
       <!--end  bullet list #2 -->

      <!-- bullet list #2 bottom border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FDC238">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="10">
          </td> 
        </tr>
      </table>
      <!-- end bullet list #2 bottom border -->

      <!-- study design top border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FECB67">
      <tr>
          <td>
              <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="10">
          </td>
        </tr>
      </table>
      <!-- end study design top border -->

      <!-- study design -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FECB67">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="30" height="1">
          </td> 
          <td>
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:400; font-size:12px; line-height:15px; color:#004B7E; letter-spacing: .2px">
              <b>Study design:</b> The MM-020 (FIRST) trial compared REVLIMID + low-dose dexamethasone (Rd) Continuous until progression, fixed-cycle MPT, and fixed-cycle Rd18. MM-020 was a Phase 3, randomized, multicenter, open-label, 3-arm study enrolling 1623 newly diagnosed patients who did not receive a stem cell transplant (SCT). REVLIMID was given 25 mg once daily orally on Days 1 to 21 of 28-day cycles, and dex was dosed once daily orally on Days 1, 8, 15, and 22 of each 28-day cycle (40 mg for patients ≤75 years and 20 mg for patients >75 years). The primary endpoint in the trial was progression-free survival (PFS), defined as the time from randomization to the first documentation of disease progression as determined by Independent Response Adjudication Committee (IRAC), based on International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurred first during the study until the end of the PFS follow-up phase. For the efficacy analysis of all endpoints, the primary comparison was between Rd Continuous and MPT arms. OS was defined as the time from randomization to death from any cause.<sup style="vertical-align: top; position: relative; top: -0.25em;">1,2</sup>             
            </font>
          </td>
        </tr>
      </table>
      <!-- end study design -->

      <!-- study design bottom border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FECB67">
      <tr>
          <td>
              <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="30">
          </td>
        </tr>
      </table>
      <!-- end study design bottom border -->

      <!-- learn more left top border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#064C7C">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="35">
          </td> 
        </tr>
      </table>
      <!-- end learn more left top border -->

      <!-- learn more left -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#064C7C">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="15" height="1">
          </td>  
          <td>
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:400; font-size:20px; line-height: 1.3em; color:#FDC238; letter-spacing: 0.40px">
                <a style="color:#FDC238;" href="http://www.revlimid.com/mm-hcp/newly-diagnosed/trial-design/" target="_blank">Learn more</a> about the
            </font>  
          </td>
        </tr>
      </table>
      
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#064C7C">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="10" height="1">
          </td>
          <td width="275"  height="1">
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:400; font-size:20px; line-height: 1.3em; color:#FDC238; letter-spacing: 0.40px">
                efficacy of REVLIMID in<br />
                patients with newly   
            </font>  
          </td>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="10" height="1">
          </td>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/large-arrow.png" width="36" height="55">
          </td>
        </tr>
      </table>
      
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#064C7C">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="15" height="1">
          </td>
          <td>
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:400; font-size:20px; line-height: 1.3em; color:#FDC238; letter-spacing: 0.40px">
                diagnosed multiple myeloma
            </font>  
          </td>
        </tr>
      </table>
      <!-- end learn more left -->

      <!-- learn more left bottom border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#064C7C">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="35">
          </td> 
        </tr>
      </table>
       <!-- end learn more left bottom border -->

    </td>   
    <!--  end left table content -->

    <!-- middle border -->   
    <td width="8" height="100%" bgcolor="#FDC2#8">
      <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="8" height="1683">
    </td>    
    <!-- end middle border -->

    <!-- right table content -->
    <td width="207" valign="top">

    <!-- Revlimid offers top border -->
    <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#004B7E">
      <tr>
        <td>
          <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="10">
        </td> 
      </tr>
    </table>
    <!-- end revlimid offers top border -->

    <!-- REVLIMID OFFERS -->
    <table width="100%" bgcolor="#064C7C" border="0" cellpadding="0" cellspacing="0">
      <tr>
        <td>
          <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="10" height="1">
        </td> 
        <td>
          <font style="font-family:Arial, Helvetica, sans-serif; font-weight:400; color:#FDC238; letter-spacing: 1px; font-size:18px; line-height:1em;">
            25.5 months median<br />
            PFS achieved with<br />
            Rd Continuous until<br /> 
            progression
          </font>
         </td>  
      </tr> 
    </table>
    <!-- end REVLIMID OFFERS -->

    <!-- learn more right top border -->
    <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#004B7E">
      <tr>
        <td>
          <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="5">
        </td> 
      </tr>
    </table>
    <!-- end learn more right top border -->
 
    <!-- Learn more right -->  
    <table width="100%" bgcolor="#064C7C">
      <tr>
        <td>
          <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="10" height="1">
        </td> 
        <td>
            <font style="font-family:Arial, Helvetica, sans-serif; font-weight:400; color:#FDC238; letter-spacing: 2px; font-size:20px; line-height:1em; text-decoration:underline;">
              <a href="Links to: http://www.revlimid.com/mm-hcp/" target="_blank" style="color:#FDC238;">Learn more</a>
            </font>
        </td>
        <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/arrow.png" width="18" height="28">
        </td>
        <td width="30">
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width=30 height="1">
        </td>
      </tr>
    </table>
    <!-- end Learn more right -->  

    <!-- learn more right bottom border -->
    <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#004B7E">
      <tr>
        <td>
          <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="5">
        </td> 
      </tr>
    </table>
    <!-- end learn more right bottom border -->

      <!-- yellow spacer row --> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FCC147">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="100%" height="11">
          </td>
        </tr>
      </table>

      <!-- ISI -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FFFFFF" style="border:2px solid #000000;">

          <!-- spacer -->
          <tr>
            <td>
              <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="5">
            </td>
          </tr>

          <tr>
            <td>
              <!-- spacer -->
              <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="5" height="1">
            </td>
            <td>
               <font style="font-family:Helvetica, Arial, sans-serif; font-weight:bold; font-size:12px; line-height: 17px; color:#000000; letter-spacing: 0px">
                  WARNING: EMBRYO-FETAL<br /> 
                  TOXICITY, HEMATOLOGIC<br /> 
                  TOXICITY, and VENOUS and<br />  
                  ARTERIAL THROMBOEMBOLISM<br /> 
                <font style="line-height: 7px;">&nbsp;</font><br />

                <font style="text-decoration:underline;">EMBRYO-FETAL TOXICITY</font><br /> 
                Do not use REVLIMID during pregnancy. Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If lenalidomide is used during pregnancy, it may cause birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting REVLIMID treatment. Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after REVLIMID treatment. To avoid embryo-fetal exposure to lenalidomide, REVLIMID is only available through a restricted distribution program, the REVLIMID REMS<sup style="vertical-align: top; position: relative; top: -0.25em;">&reg;</sup> program (formerly known as the "RevAssist<sup style="vertical-align: top; position: relative; top: -0.25em;">&reg;</sup>" program).<br /> 
          
                <font style="line-height: 7px;">&nbsp;</font><br /> 
                
                Information about the REVLIMID REMS<sup style="vertical-align: top; position: relative; top: -0.25em;">&reg;</sup> program is available at<br /> 

                <font style="font-size:11px;">
                  <a href="https://www.celgeneriskmanagement.com/REMSPortal/rems/portal/REMSPortal.portal" target="_blank" style="color:#004b7E;">www.celgeneriskmanagement.com</a></font><br />

                or by calling the manufacturer’s toll-free number 1-888-423-5436.<br />

                <font style="line-height: 8px;">&nbsp;</font><br />

                <font style="text-decoration:underline;"> 
                  Hematologic Toxicity<br />  
                  (Neutropenia and<br /> 
                  Thrombocytopenia)
                </font>

                <br /> 

                REVLIMID can cause significant neutropenia and thrombocytopenia. Eighty percent of patients with del 5q MDS had to have a dose delay/reduction during the major study. Thirty-four percent of patients had to have a second dose delay/reduction. Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled in the study. Patients on therapy for del 5q MDS should have their complete blood counts monitored weekly for the first 8 weeks of therapy and at least monthly thereafter. Patients may require dose interruption and/or reduction. Patients may require use of blood product support and/or <span style="white-space: nowrap;">growth factors.</span><br /> 

                <font style="line-height: 8px;">&nbsp;</font><br />

                <font style="text-decoration:underline;"> 
                  Venous and Arterial<br /> 
                  Thromboembolism
                </font>

                <br /> 

                REVLIMID has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and stroke in patients with MM who were treated with REVLIMID and dexamethasone therapy. Monitor for and advise patients about signs and symptoms of thromboembolism. Advise patients to seek immediate medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. Thromboprophylaxis is recommended and the choice regimen should be based on an assessment of the patient’s <span style="white-space: nowrap;">underlying risks.<s/pan><br />

              </font>
            </td>
            <td>
              <!-- spacer -->
              <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="5" height="1">
            </td>
          </tr>
          <!-- spacer -->
          <tr>
            <td>
              <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="5">
            </td>
          </tr>
      </table>
      <!-- end ISI -->

      <!-- visit revlimid.com 1 -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FDC238">
          <tr>
            <td height="58" style="padding:0 0 0 20px">
                <font style="font-family:Helvetica, Arial, sans-serif; font-weight:bold; font-size:14px; line-height: 17px; color:#004b7e; letter-spacing: 0px">
                  For more information,<br />
                  visit <a style="color:#004b7e;" href="http://www.revlimid.com/mm-hcp/" target="_blank">www.REVLIMID.com</a>
                </font>
            </td>
          </tr>
      </table>
      <!-- end visit revlimid.com -->

    </td>
    <!-- end right table content -->

    <!-- right border -->
      <td width="9" height="100%" bgcolor="#FDC2#8">
        <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="8" height="1683">
      </td>    
    <!-- end right border -->
 
</tr>
</table>
<!-- end double table-->

<!-- important safety information continued -->
<table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FFFFFF">
  <tr>

    <!-- isi left border -->
    <td >
      <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="25" height="1">
    </td> 

    <!-- isi center square --> 
    <td>
      
      <!-- isi top border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="20">
          </td> 
        </tr>
      </table>

      <!-- content -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#FFFFFF">

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:600; font-size:19px; line-height: 1em; color:#004b7e; letter-spacing: 0px">
          Important Safety Information (continued)
          </font>
        </p>

        <p>
            <font style="font-family:Helvetica, Arial, sans-serif; font-weight:600; font-size:16px; line-height: 1em; color:#18BEE7; letter-spacing: 0px">
              CONTRAINDICATIONS
            </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            <b>Pregnancy:</b> REVLIMID can cause fetal harm when administered to a pregnant female and is contraindicated in females who are pregnant. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to <span style="white-space: nowrap;">the fetus</span>
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            <b>Allergic Reactions:</b> REVLIMID is contraindicated in patients who have demonstrated hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) <span style="white-space: nowrap;">to lenalidomide</span>
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:600; font-size:16px; line-height: 1em; color:#18BEE7; letter-spacing: 0px">
            WARNINGS AND PRECAUTIONS
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            <b>Embryo-Fetal Toxicity:</b>
            <ul>
              <li>
                <span>
                  REVLIMID is an analogue of thalidomide, a known human teratogen that causes life-threatening human birth defects or embryo-fetal death. An embryo-fetal development study in monkeys indicates that lenalidomide produced malformations in offspring of female monkeys who received drug during pregnancy, similar to birth defects observed in humans following exposure to thalidomide <span style="white-space: nowrap;">during pregnancy</span>
                </span>
              </li>
              <li>
                <span>
                  Females of Reproductive Potential: Must avoid pregnancy for at least 4 weeks before beginning REVLIMID therapy, during therapy, during dose interruptions and for at least 4 weeks after completing therapy. Must commit either to abstain continuously from heterosexual sexual intercourse or to use two methods of reliable birth control beginning 4 weeks prior to initiating treatment with REVLIMID, during therapy, during dose interruptions and continuing for 4 weeks following discontinuation of REVLIMID. Must obtain 2 negative pregnancy tests prior to <span style="white-space: nowrap;">initiating therapy</span>
                </span>
              </li>
              <li>
                <span>
                  Males: Lenalidomide is present in the semen of patients receiving the drug. Males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking REVLIMID and for up to 28 days after discontinuing REVLIMID, even if they have undergone a successful vasectomy. Male patients taking REVLIMID must not <span style="white-space: nowrap;">donate sperm</span>
                </span>
              </li>
              <li>
                <span>
                  Blood Donation: Patients must not donate blood during treatment with REVLIMID and for 1 month following discontinuation of the drug because the blood might be given to a pregnant female patient whose fetus must not be exposed <span style="white-space: nowrap;">to REVLIMID</span>
                </span>
              </li>
            </ul>
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:600; font-size:16px; line-height: 1em; color:#18BEE7; letter-spacing: 0px">
            REVLIMID REMS<sup style="vertical-align: top; position: relative; top: -0.25em;">&reg;</sup> Program
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            Because of embryo-fetal risk, REVLIMID is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) the <b>REVLIMID REMS<sup style="vertical-align: top; position: relative; top: -0.25em;">&reg;</sup></b> program (<b>formerly known as the “RevAssist<sup style="vertical-align: top; position: relative; top: -0.25em;">&reg;</sup>” program</b>). Prescribers and pharmacies must be certified with the program and patients must sign an agreement form and comply with the requirements. Further information about the REVLIMID REMS<sup style="vertical-align: top; position: relative; top: -0.25em;">&reg;</sup> program is available at <a href="https://www.celgeneriskmanagement.com/REMSPortal/rems/portal/REMSPortal.portal" target="_blank">www.celgeneriskmanagement.com</a> or by telephone at 1-888-423-5436
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            <b>Hematologic Toxicity:</b> REVLIMID can cause significant neutropenia and thrombocytopenia. Monitor patients with neutropenia for signs of infection. Advise patients to observe for bleeding or bruising, especially with use of concomitant medications that may increase risk of bleeding. <b>MM:</b> Patients taking REVLIMID/dex should have their complete blood counts (CBC) assessed every 7 days for the first 2 cycles, on days 1 and 15 of cycle 3, and every 28 <span style="white-space: nowrap;">days thereafter.</span>
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            <b>Venous and Arterial Thromboembolism:</b> Venous thromboembolic events (DVT and PE) and arterial thromboses are increased in patients treated with REVLIMID. A significantly increased risk of DVT (7.4%) and PE (3.7%) occurred in patients with MM after at least one prior therapy, treated with REVLIMID/dex compared to placebo/dex (3.1% and 0.9%) in clinical trials with varying use of anticoagulant therapies. In NDMM study, in which nearly all patients received antithrombotic prophylaxis, DVT (3.6%) and PE (3.8%) were reported in the Rd continuous arm. Myocardial infarction (MI, 1.7%) and stroke (CVA, 2.3%) are increased in patients with MM after at least 1 prior therapy who were treated with REVLIMID/dex therapy compared with placebo/dex (0.6%, and 0.9%) in clinical trials. In NDMM study, MI (including acute) was reported (2.3%) in the Rd Continuous arm. Frequency of serious adverse reactions of CVA was (0.8%) in the Rd Continuous arm. Patients with known risk factors, including prior thrombosis, may be at greater risk and actions should be taken to try to minimize all modifiable factors (e.g. hyperlipidemia, hypertension, smoking). In controlled clinical trials that did not use concomitant thromboprophylaxis, 21.5% overall thrombotic events occurred in patients with refractory and relapsed MM who were treated with REVLIMID/dex compared to 8.3% thrombosis in the placebo/dex group. Median time to first thrombosis event was 2.8 months. In NDMM study, which nearly all patients received antithrombotic prophylaxis, overall frequency of thrombotic events was 17.4% in combined Rd Continuous and Rd18 arms. Median time to first thrombosis event was 4.37 months. Thromboprophylaxis is recommended and regimen is based on patients underlying risks. ESAs and estrogens may further increase the risk of thrombosis and their use should be based on a benefit-risk decision. <span style="white-space: nowrap;"><b>See Boxed WARNINGS</b></span>
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            <b>Increased Mortality in Patients With CLL:</b> In a clinical trial in the first line treatment of patients with CLL, single agent REVLIMID therapy increased the risk of death as compared to single agent chlorambucil. In an interim analysis, there were 34 deaths among 210 patients on the REVLIMID treatment arm compared to 18 deaths among 211 patients in the chlorambucil treatment arm, and hazard ratio for overall survival was 1.92 [95% CI: 1.08-3.41] consistent with a 92% increase in risk of death. Serious adverse cardiovascular reactions, including atrial fibrillation, myocardial infarction, and cardiac failure, occurred more frequently in the REVLIMID treatment arm. REVLIMID is not indicated and not recommended for use in CLL outside of controlled <span style="white-space: nowrap;">clinical trials</span>
          <font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            <b>Second Primary Malignancies:</b> In clinical trials in patients with MM receiving REVLIMID, an increase of invasive second primary malignancies (SPM) notably AML and MDS have been observed. The increase of AML and MDS occurred predominantly in NDMM patients receiving REVLIMID in combination with oral melphalan (5.3%) or immediately following high dose intravenous melphalan and ASCT (up to 5.2%). The frequency of AML and MDS cases in the Revlimid/dex arms was observed to be 0.4%. Cases of B-cell malignancies (including Hodgkin’s Lymphomas) were observed in clinical trials where patients received REVLIMID in the post-ASCT setting. Patients who received REVLIMID-containing therapy until disease progression did not show a higher incidence of invasive SPM than patients treated in the fixed duration REVLIMID-containing arms. Monitor patients for the development of second primary malignancies. Take into account both the potential benefit of REVLIMID and risk of second primary malignancies when <span style="white-space: nowrap;">considering treatment</span>
          <font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            <b>Hepatotoxicity:</b> Hepatic failure, including fatal cases, has occurred in patients treated with Revlimid in combination with dex. The mechanism of drug-induced hepatotoxicity is unknown. Pre-existing viral liver disease, elevated baseline liver enzymes, and concomitant medications may be risk factors. Monitor liver enzymes periodically. Stop REVLIMID upon elevation of liver enzymes. After return to baseline values, treatment at a lower dose may <span style="white-space: nowrap;">be considered</span>
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            <b>Allergic Reactions:</b> Angioedema and serious dermatologic reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported. These events can be fatal. Patients with a prior history of Grade 4 rash associated with thalidomide treatment should not receive REVLIMID. REVLIMID interruption or discontinuation should be considered for Grade 2-3 skin rash. REVLIMID must be discontinued for angioedema, Grade 4 rash, exfoliative or bullous rash, or if SJS or TEN is suspected and should not be resumed following discontinuation for these reactions. REVLIMID capsules contain lactose. Risk-benefit of REVLIMID treatment should be evaluated in patients with <span style="white-space: nowrap;">lactose intolerance</span>
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            <b>Tumor Lysis Syndrome:</b> Fatal instances of tumor lysis syndrome (TLS) have been reported during treatment with lenalidomide. The patients at risk of TLS are those with high tumor burden prior to treatment. These patients should be monitored closely and appropriate <span style="white-space: nowrap;">precautions taken</span>
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            <b>Tumor Flare Reaction:</b> Tumor flare reaction (TFR) has occurred during investigational use of lenalidomide for CLL and lymphoma, and is characterized by tender lymph node swelling, low grade fever, <span style="white-space: nowrap;">pain and rash</span>
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            <b>Impaired Stem Cell Mobilization:</b> A decrease in the number of CD34+ cells collected after treatment (> 4 cycles) with REVLIMID has been reported. In patients who are autologous stem cell transplant (ASCT) candidates, referral to a transplant center should occur early in treatment to optimize timing of the stem <span style="white-space: nowrap;">cell collection</span>
          <font>
          </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:600; font-size:16px; line-height: 1em; color:#18BEE7; letter-spacing: 0px">
            ADVERSE REACTIONS
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            <b><u>Multiple Myeloma</u></b>
            <ul>
              <li>
                <span>
                  <b>In newly diagnosed patients</b> the most frequently reported Grade 3 or 4 adverse reactions in Arm Rd Continuous included neutropenia (27.8%), anemia (18.2%), thrombocytopenia (8.3%), pneumonia (11.3%), asthenia (7.7.%), fatigue (7.3%), back pain (7%), hypokalemia (6.6%), rash (7.3%), cataract (5.8%), dyspnea (5.6%), DVT (5.6%), hyperglycemia (5.3%), lymphopenia and leukopenia. The frequency of infections in Arm Rd Continuous <span style="white-space: nowrap;">was 75%</span>
                </span>
              </li>
              <li>
                <span>
                  Adverse reactions reported in ≥20% of NDMM patients in Arm Rd Continuous: diarrhea (45.5%), anemia (43.8%), neutropenia (35%), fatigue (32.5%), back pain (32%), insomnia (27.6%), asthenia (28.2%), rash (26.1%), decreased appetite (23.1%), cough (22.7%), pyrexia (21.4%), muscle spasms (20.5%), and abdominal pain (20.5%). The frequency of onset of cataracts increased over time with 0.7% during the first 6 months and up to 9.6% by the second year of treatment with Arm <span style="white-space: nowrap;">Rd Continuous</span>
                </span>
              </li>  
              <li>
                <span>
                  <b>After at least one prior therapy</b> most adverse reactions and Grade 3 or 4 adverse reactions were more frequent in MM patients who received the combination of REVLIMID/dex compared to placebo/dex. Grade 3 or 4 adverse reactions included neutropenia 33.4% vs 3.4%, febrile neutropenia 2.3% vs 0%, DVT 8.2% vs 3.4% and PE 4% vs <span style="white-space: nowrap;">0.9% respectively</span>
                </span>
              </li>
            </ul>
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            Adverse reactions reported in ≥15% of MM patients (REVLIMID/dex vs dex/placebo): fatigue (44% vs 42%), neutropenia (42% vs 6%), constipation (41% vs 21%), diarrhea (39% vs 27%), muscle cramp (33% vs 21%), anemia (31% vs 24%), pyrexia (28% vs 23%), peripheral edema (26% vs 21%), nausea (26% vs 21%), back pain (26% vs 19%), upper respiratory tract infection (25% vs 16%), dyspnea (24% vs 17%), dizziness (23% vs 17%), thrombocytopenia (22% vs 11%), rash (21% vs 9%), tremor (21% vs 7%), weight decreased (20% vs 15%), nasopharyngitis (18% vs 9%), blurred vision (17% vs 11%), anorexia (16% vs 10%), and dysgeusia <span style="white-space: nowrap;">(15% vs 10%)</span>
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:600; font-size:16px; line-height: 1em; color:#18BEE7; letter-spacing: 0px">
            DRUG INTERACTIONS
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            Periodic monitoring of digoxin plasma levels, in accordance with clinical judgment and based on standard clinical practice in patients receiving this medication, is recommended during administration of REVLIMID. It is not known whether there is an interaction between dex and warfarin. Close monitoring of PT and INR is recommended in MM patients taking concomitant warfarin. Erythropoietic agents, or other agents, that may increase the risk of thrombosis, such as estrogen containing therapies, should be used with caution after making a benefit-risk assessment in patients <span style="white-space: nowrap;">receiving REVLIMID</span>
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:600; font-size:16px; line-height: 1em; color:#18BEE7; letter-spacing: 0px">
            USE IN SPECIFIC POPULATIONS
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            <b>Pregnancy:</b> If pregnancy does occur during treatment, immediately discontinue the drug. Under these conditions, refer patient to an obstetrician/gynecologist experienced in reproductive toxicity for further evaluation and counseling. Any suspected fetal exposure to REVLIMID must be reported to the FDA via the MedWatch program at 1-800-332-1088 and also to Celgene Corporation at 1-888-423-5436
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            <b>Nursing Mothers:</b> It is not known whether REVLIMID is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to <span style="white-space: nowrap;">the mother</span>
          </font>
          </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            <b>Pediatric Use:</b>  Safety and effectiveness in patients below the age of 18 have not <span style="white-space: nowrap;">been established</span>
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:200; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            <b>Renal Impairment:</b> Since REVLIMID is primarily excreted unchanged by the kidney, adjustments to the starting dose of REVLIMID are recommended to provide appropriate drug exposure in patients with moderate (CLcr 30-60 mL/min) or severe renal impairment (CLcr < 30 mL/min) and in patients <span style="white-space: nowrap;">on dialysis</span>
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:600; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            Please click for full <a href="http://www.revlimid.com/wp-content/uploads/2013/11/PI.pdf" target="_blank">Prescribing Information</a>, including Boxed WARNINGS.
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:600; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            Reference:
          </font>
        </p>

        <p>
          <font style="font-family:Helvetica, Arial, sans-serif; font-weight:600; font-size:14px; line-height: 1em; color:#000000; letter-spacing: 0px">
            1. REVLIMID [package insert]. Summit, NJ: Celgene Corporation. 2015.
          </font>
        </p>
      </table>
      <!-- end content -->

      <!-- isi bottom border -->
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr>
          <td>
            <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="15">
          </td> 
        </tr>
      </table>

    </td>  
    <!-- end isi center square -->

    <!-- isi right border -->
    <td>
      <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="20" height="1">
    </td>   

  </tr>
</table>
<!-- end important safety information continued-->

<!-- footer top border -->
<table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#DDDDDD">
  <tr>
    <td>
      <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="20">
    </td> 
  </tr>
</table>
<!-- end footer top border -->

<!-- footer table 1 -->
 <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#DDDDDD">
 	<tr>
      <td>
        <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="20" height=" 1">
      </td> 
    	<td>
        <font style="font-family:Arial, Helvetica, sans-serif; font-weight:normal; color: #626366; font-size: 10px;letter-spacing: .062em; line-height: 1.3em;">
            <p>
            This e-mail was sent by Celgene Corporation and is intended for U.S. healthcare providers only.
            </p>
            <p>
            Celgene Corporation, 86 Morris Avenue, Summit, New Jersey 07901
            </p>
            <p style="line-height:1.2em;">
            To no longer receive these messages from Celgene about REVLIMID concerning multiple myeloma,<br />
            please <a href=" http://www.celgenesubscriptioncenter.com/contacts/optout/25?key=$email" target="_blank">click here</a> to unsubscribe from this email list.
          </p>
          <p>
            To manage your Celgene communications, <a href=" http://www.celgenesubscriptioncenter.com/contacts/subscriptions?key=$email" target="_blank">click here</a>.
          </p>
        </font>
      </td>

  </tr>
</table>
<!-- end footer table 1 -->
 
<!-- footer table 2 -->
<table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#DDDDDD">
  <tr>

 	  <td width="32" height="140">
      <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="32" height="140">
    </td>

    <td>
      <a href="http://www.celgene.com/" target="_blank">
        <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/celgene-logo.png" width="83" height="76" border="0">
      </a>
    </td>

    <td width="12" height="140">
      <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="12" height="140">
    </td>

    <td width="494">
      <font style="font-family:Arial, Helvetica, sans-serif; font-weight:normal; color: #626366; font-size: 12px;letter-spacing: .005em; line-height:22px;">
          REVLIMID<sup style="vertical-align: top; position: relative; top: -0.25em;">&reg;</sup> and REVLIMID REMS<sup style="vertical-align: top; position: relative; top: -0.25em;">&reg;</sup> are registered trademarks of Celgene Corporation.<br />
          &nbsp;&copy; <span style="word-spacing:57px;">2015 </span>Celgene Corporation<span style="word-spacing:57px;">  07/15     US-REV150107</span><br />
        </font>
    </td>
  </tr>
</table>
<!-- end footer Table 2 -->

<!-- footer bottom border -->
<table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#DDDDDD">
  <tr>
    <td>
      <img src="http://kidneyconf2012.com/arx/CPS_Veeva_Email/pfs-os/img/spacer.gif" width="1" height="10">
    </td> 
  </tr>
</table>
<!-- end footer bottom border -->

</td>
</tr>
</table>
 <!-- end wrapper -->   

</body>
</html>